292 related articles for article (PubMed ID: 27206567)
21. Impact of lorcaserin on glycemic control in overweight and obese patients with type 2 diabetes: analysis of week 52 responders and nonresponders.
Pi-Sunyer X; Shanahan W; Fain R; Ma T; Garvey WT
Postgrad Med; 2016 Aug; 128(6):591-7. PubMed ID: 27389084
[TBL] [Abstract][Full Text] [Related]
22. Lorcaserin: a review of its use in chronic weight management.
Hoy SM
Drugs; 2013 Apr; 73(5):463-73. PubMed ID: 23529825
[TBL] [Abstract][Full Text] [Related]
23. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study.
O'Neil PM; Smith SR; Weissman NJ; Fidler MC; Sanchez M; Zhang J; Raether B; Anderson CM; Shanahan WR
Obesity (Silver Spring); 2012 Jul; 20(7):1426-36. PubMed ID: 22421927
[TBL] [Abstract][Full Text] [Related]
24. Effects of lorcaserin on fat and lean mass loss in obese and overweight patients without and with type 2 diabetes mellitus: the BLOSSOM and BLOOM-DM studies.
Apovian C; Palmer K; Fain R; Perdomo C; Rubino D
Diabetes Obes Metab; 2016 Sep; 18(9):945-8. PubMed ID: 27173586
[TBL] [Abstract][Full Text] [Related]
25. Lorcaserin and adiposopathy: 5-HT2c agonism as a treatment for 'sick fat' and metabolic disease.
Bays HE
Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1429-45. PubMed ID: 19900026
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic drug evaluation of extended release lorcaserin for the treatment of obesity.
Hurren KM; Dunham MW
Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):891-896. PubMed ID: 28636828
[TBL] [Abstract][Full Text] [Related]
27. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women.
Smith SR; Prosser WA; Donahue DJ; Morgan ME; Anderson CM; Shanahan WR;
Obesity (Silver Spring); 2009 Mar; 17(3):494-503. PubMed ID: 19057523
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of lorcaserin in obesity: a systematic review and meta-analysis of randomized controlled trials.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2020 Feb; 13(2):183-190. PubMed ID: 31815555
[No Abstract] [Full Text] [Related]
29. Lorcaserin for the treatment of obesity.
Redman LM; Ravussin E
Drugs Today (Barc); 2010 Dec; 46(12):901-10. PubMed ID: 21589947
[TBL] [Abstract][Full Text] [Related]
30. ACS chemical neuroscience molecule spotlight on Lorcaserin.
Hopkins CR
ACS Chem Neurosci; 2010 Nov; 1(11):718-9. PubMed ID: 22778808
[TBL] [Abstract][Full Text] [Related]
31. Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure.
Martin CK; Redman LM; Zhang J; Sanchez M; Anderson CM; Smith SR; Ravussin E
J Clin Endocrinol Metab; 2011 Mar; 96(3):837-45. PubMed ID: 21190985
[TBL] [Abstract][Full Text] [Related]
32. Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential.
Higgins GA; Fletcher PJ; Shanahan WR
Pharmacol Ther; 2020 Jan; 205():107417. PubMed ID: 31629010
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of Cocaine and 3,4-Methylenedioxypyrovalerone (MDPV) Self-Administration by Lorcaserin Is Mediated by 5-HT2C Receptors in Rats.
Gannon BM; Sulima A; Rice KC; Collins GT
J Pharmacol Exp Ther; 2018 Mar; 364(2):359-366. PubMed ID: 29217539
[TBL] [Abstract][Full Text] [Related]
34. From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists.
Higgins GA; Sellers EM; Fletcher PJ
Trends Pharmacol Sci; 2013 Oct; 34(10):560-70. PubMed ID: 24041919
[TBL] [Abstract][Full Text] [Related]
35. Serotonergic anti-obesity agents: past experience and future prospects.
Halford JC; Boyland EJ; Lawton CL; Blundell JE; Harrold JA
Drugs; 2011 Dec; 71(17):2247-55. PubMed ID: 22085383
[TBL] [Abstract][Full Text] [Related]
36. Safety assessment of FDA-approved (orlistat and lorcaserin) anti-obesity medications.
Halpern B; Halpern A
Expert Opin Drug Saf; 2015 Feb; 14(2):305-15. PubMed ID: 25563411
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the abuse potential of lorcaserin, a serotonin 2C (5-HT2C) receptor agonist, in recreational polydrug users.
Shram MJ; Schoedel KA; Bartlett C; Shazer RL; Anderson CM; Sellers EM
Clin Pharmacol Ther; 2011 May; 89(5):683-92. PubMed ID: 21412231
[TBL] [Abstract][Full Text] [Related]
38. Effects of 5-HT
Higgins GA; Brown M; St John J; MacMillan C; Silenieks LB; Thevarkunnel S
Neuropharmacology; 2020 Jun; 170():108064. PubMed ID: 32222404
[TBL] [Abstract][Full Text] [Related]
39. The serotonin-2C agonist Lorcaserin delays intravenous choice and modifies the subjective and cardiovascular effects of cocaine: A randomized, controlled human laboratory study.
Pirtle JL; Hickman MD; Boinpelly VC; Surineni K; Thakur HK; Grasing KW
Pharmacol Biochem Behav; 2019 May; 180():52-59. PubMed ID: 30811963
[TBL] [Abstract][Full Text] [Related]
40. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
